Search

everythinglearnresearchcommunity

for

Search:↓

Ethinylestradiol/chlormadinone acetate may be an effective and well-tolerated treatment for skin conditions caused by excess androgens.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

Androgen replacement therapy can improve libido and mood in women with severe androgen deficiency, but more research is needed on its long-term safety.

Understanding normal hair growth and loss in children is key to diagnosing and treating hair disorders.

The birth control pill containing ethinylestradiol and chlormadinone may help treat acne and other skin and hair conditions related to hormones.

Androgen receptors are active in many tissues of both male and female mice, not just reproductive organs.

Finasteride shows promise for treating hair loss and excessive hair growth, but more research is needed to confirm its effectiveness and safety.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

The review concludes that innovations in regenerative medicine, tissue engineering, and developmental biology are essential for effective tissue repair and organ transplants.

Hyperadrenocorticism in ferrets is linked to neutering and indoor housing, and is best treated with surgery and a deslorelin implant.

A new mRNA variant of the SCF gene in sheep skin produces a shorter, different protein.

Genetic defects in testosterone production can cause hormonal and developmental disorders, and more research is needed to understand androgen regulation and develop safer treatments.

Androgens play a key role in hair growth and disorders like baldness and excessive hairiness.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Hirsutism is excessive hair growth in women often caused by polycystic ovarian syndrome, and identifying the cause is important for managing associated health risks.

Accurate diagnosis is key for treating different kinds of hair loss, and immune response variations may affect the condition and treatment results.

For women with moderate to severe unwanted hair growth or acne, birth control pills are the first choice, with other medications like cyproterone, spironolactone, flutamide, or finasteride as alternatives, and permanent hair removal should be done with electrolysis or laser.

AGA affects many, progresses differently, and early treatment is crucial.

Hirsutism in women is often due to hormone sensitivity and has significant psychological effects.

Topical minoxidil is the most promising treatment for male pattern hair loss, but more research is needed to confirm its effectiveness and safety.

High androgen levels in postmenopausal women may suggest an ovarian tumor, and removing it can improve heart and metabolic health.

Placenta products might help with hair loss, but more research is needed.

Testosterone therapy can help postmenopausal women with low sexual desire but needs more safety research and should be used with estrogen therapy.

Testosterone therapy can help with androgen deficiency in women but should be used with caution and monitoring due to potential risks.

The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.

Testosterone therapy can help improve sexual function, mood, and bone density in women with low androgen levels, but more research is needed on long-term safety.

Patients with PCOS rate their hirsutism higher than clinicians, and these self-ratings are more closely related to their quality of life and risk of depression.

The document concludes that more research is needed to understand excessive hair growth in women with normal hormone levels and regular ovulation.

Hormonal therapies help treat female hair loss, but results are slow and vary.

The MAGE3 hypothesis for alopecia areata did not lead to a significant breakthrough.